Eyedentity has raised €1.3m to develop its AI diagnostics platform, pursue regulatory approval and expand into opticians, eye clinics and hospitals.
The MedTech startup is developing technology to detect serious eye diseases using fundus images already captured during routine eye examinations.
Its first application focuses on uveal melanoma, a rare but potentially deadly eye cancer that can be difficult to distinguish from benign conditions, particularly at an early stage.
Gustav Stålhammar, co-founder and chief scientific officer, said: “A huge number of images are already taken at opticians, and there is a trend that opticians in particular are getting an increasingly large group of patients, for example people seeking help for vision problems, dry eyes or other problems.”
Eyedentity’s technology is designed to work within the infrastructure already used by opticians.
Existing fundus images can be uploaded to its platform, which analyses them and provides decision support on whether a patient should be referred to a specialist.
The company says the system can reduce false-positive referrals by 90 per cent. This could help specialist eye-care services prioritise patients requiring further investigation while reducing unnecessary referrals.
Founded in 2025, Eyedentity was established by a team with experience in ophthalmology, machine learning and company building.
Stålhammar is an ocular oncologist at St. Erik Eye Hospital and professor at Karolinska Institutet, while co-founder and chief executive Mats Holmström previously worked on machine learning applications for automating cancer care at RaySearch Laboratories.
The investment round was led by Norrsken Launcher, with participation from Karolinska Institutet Innovation and a group of angel investors.
Anna Fredrixon, partner at Norrsken Launcher, said: “This is a clear example of technology that can save lives but, unlike other AI companies, does not send more patients to an already overburdened healthcare system.
“This is a win-win. And what’s more, no new infrastructure is needed. It’s brilliant, and ready to roll out now.”
Eyedentity is also part of the Karolinska Institutet Innovation Incubator and is running a live pilot with Synologen, a network of independent opticians in Sweden.
The company plans to move from the pilot towards commercialisation in the Nordics before expanding across Europe and the US.
The new capital will be used to work towards full regulatory approval for Eyedentity’s first product, develop additional diagnostic capabilities and grow its team ahead of wider commercial deployment.
Beyond uveal melanoma, the company plans to develop its platform for other eye diseases, including diabetic retinopathy and glaucoma, with the longer-term aim of supporting diagnostics across multiple conditions.
